open access

Vol 11, No 2 (2015)
Review paper
Published online: 2015-05-20
Get Citation

Mechanism of action, efficacy and safety of long-acting granulocyte-colony stimulating factors (G-CSFs) in neutropenia associated with myelotoxic chemotherapy

Wojciech Rogowski
Onkol. Prak. Klin 2015;11(2):87-92.

open access

Vol 11, No 2 (2015)
REVIEW ARTICLES
Published online: 2015-05-20

Abstract

Granulocyte-colony stimulating factors (G-CSFs) have been used in the prevention and treatment of severe neutropenia associated with myelotoxic chemotherapy since 1990s. In the recent years, long-active recombinant G-CSFs — pegfilgrastim and lipegfilgrastim — were introduced. The review of available literature data suggests that the long-acting recombinant G-CSFs are characterized by a favorable pharmacokinetic profile after administration at a single dose of 6 mg per cytotoxic chemotherapy cycle. Clinical trials showed that the efficacy of both agents administered at the single dose is comparable to that of short-acting human recombinant G-CSF, filgrastim, injected daily after the course of chemotherapy. Both, the above mentioned evidence and satisfactory adverse event profile of the long-acting recombinant G-CSFs suggest that these agents should be routinely used in all patients at risk of severe neutropenia related to myelosupressive chemotherapy.

Abstract

Granulocyte-colony stimulating factors (G-CSFs) have been used in the prevention and treatment of severe neutropenia associated with myelotoxic chemotherapy since 1990s. In the recent years, long-active recombinant G-CSFs — pegfilgrastim and lipegfilgrastim — were introduced. The review of available literature data suggests that the long-acting recombinant G-CSFs are characterized by a favorable pharmacokinetic profile after administration at a single dose of 6 mg per cytotoxic chemotherapy cycle. Clinical trials showed that the efficacy of both agents administered at the single dose is comparable to that of short-acting human recombinant G-CSF, filgrastim, injected daily after the course of chemotherapy. Both, the above mentioned evidence and satisfactory adverse event profile of the long-acting recombinant G-CSFs suggest that these agents should be routinely used in all patients at risk of severe neutropenia related to myelosupressive chemotherapy.

Get Citation

Keywords

immunosuppression, myelotoxicity, pharmacodynamics, adverse events, filgrastim, pegfilgrastim, lipegfilgrastim

About this article
Title

Mechanism of action, efficacy and safety of long-acting granulocyte-colony stimulating factors (G-CSFs) in neutropenia associated with myelotoxic chemotherapy

Journal

Oncology in Clinical Practice

Issue

Vol 11, No 2 (2015)

Article type

Review paper

Pages

87-92

Published online

2015-05-20

Bibliographic record

Onkol. Prak. Klin 2015;11(2):87-92.

Keywords

immunosuppression
myelotoxicity
pharmacodynamics
adverse events
filgrastim
pegfilgrastim
lipegfilgrastim

Authors

Wojciech Rogowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl